Back

Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study

29 August 2022 (08:15 - 09:00)
Organised by:
Congress Presentation Part of: Coronary artery disease - Pharmacotherapy 3 Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Alessandro Spirito

Heart Clinic Lucerne, Lucerne (Switzerland)

6 More presentations in this session

Presentation thumbnail
Effect of exercise-based cardiac rehabilitation on the ischemic threshold in patients with high-risk ischemic heart disease
Doctor J. Lara Vargas (Ciudad de Mexico, MX)
Abstract Slides
Presentation thumbnail
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis of cohort studies
Mr S. Soulaidopoulos (Athens, GR)
Abstract Slides
Presentation thumbnail
Low dose rivaroxaban therapy in aspirin allergic patients undergoing percutaneous coronary intervention
Doctor S. Manjooran (London, GB)
Abstract Slides
Presentation thumbnail
Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial
Doctor S. Patel (Boston, US)
Abstract Slides
Presentation thumbnail
Thrombin generation and endothelial progenitor cell function among patients with acute myocardial infarction treated with prasugrel versus ticagrelor
Doctor M. Wiessman (Dallas, US)
Abstract Slides

Access the full session

Session thumbnail
Coronary artery disease - Pharmacotherapy 3

The Event

Event poster

ESC Congress 2022

29 August 2022 08:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources